plenty of upside coming for this company. http://www.psivida.com/News/download/Presentations/Rodman%20&%20Renshaw%20May%202008.pdf
Company Highlights
Proven drug delivery business model
Complementary and broadly-applicable technologies • Well positioned in Ophthalmology • Potential to expand into other fields
FDA Approved Products on the Market • Retisert is the only FDA approved product for posterior uveitis • Vitrasert approved in US, EU, and Japan for CMV retinitis
Broad and well-balanced R&D pipeline • Medidur for diabetic macular edema (DME) – Phase III pivotal trials • BrachySil for pancreatic cancer – Entering Phase IIb trials • Significant collaboration agreement with Pfizer
Upside for Shareholders
Significant revenue potential from fully funded ophthalmic programs with different partners (in DME, age related macular degeneration and others)
Possible additional partnerships from BioSilicon technology, (furthest advanced application in Phase II trials)
Anticipate reincorporation as US-based, NASDAQ-listed company
PSD Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held